Krsnaa Diagnostics Receives Preferential Warrant Approval

The company has received in-principle approval from both BSE Limited and National Stock Exchange of India Limited for:

Issue of 16,21,000 convertible warrants
Warrants convertible into 16,21,000 equity shares of face value ₹5 each
Issue price: ₹566 per warrant
Allottees: Promoter and Promoter Group of the company
Basis: Preferential issue under Regulation 28(1) of SEBI (LODR) Regulations, 2015

Total issue size: 16,21,000 warrants
Potential equity dilution: 16,21,000 shares upon conversion
Total funds raised: Approximately ₹91.75 crore (16,21,000 warrants × ₹566 per warrant)

The in-principle approval is subject to the company fulfilling the following conditions:

1. Filing listing application promptly after allotment

2. Obtaining statutory approvals from SEBI, RBI, MCA, and other authorities

3. Compliance with all applicable guidelines, regulations, and directions

4. Compliance with SEBI (LODR) Regulations, 2015, Companies Act, and other applicable laws

5. Submission of required documents and payment of applicable fees to NSE

NSE specifically advised the company to strengthen internal controls to monitor trades by proposed allottees:

Company must obtain undertaking from allottees confirming they will not engage in intra-day trading or any sale in the company scrip until the allotment date
Responsibility for verification and compliance rests solely with the issuer company
Non-compliances may impact listing of the shares

BSE approval letter contains factual errors requiring rectification; corrected letter to be intimated separately
The approval does not constitute approval under any other Act/Regulation/rule/byelaws
Exchange reserves right to withdraw approval if information is found incomplete/incorrect/misleading/false

The information is available on the company's website at https://krsnaadiagnostics.com/investors/